The dilemma of Tocilizumab therapy for a patient with critical COVID-19
disease and neutropenia: Case report and review of the literature
- Ahmad Al Bishawi
, - Shiema Abdalla,
- Marwa Askar,
- Wael Kanjo,
- Amal Sameer,
- Gihan Mustafa,
- Hamad Abdel Hadi,
- Muna AlMaslamani,
- Alaaeldin Abdelmajid
Abstract
Our patient is a 39-year-old male with normal baseline blood parameters
who presented with COVID-19 infection, associated with neutropenia and
then progressed to critical disease culminating into CSS. Based on risks
and benefits evaluation, he was treated with Tocilizumab reinforced with
G-CSF leading to full recovery including reversal of neutropenia.19 Feb 2022Submitted to Clinical Case Reports 21 Feb 2022Submission Checks Completed
21 Feb 2022Assigned to Editor
09 Apr 2022Reviewer(s) Assigned
21 Apr 2022Review(s) Completed, Editorial Evaluation Pending
26 Apr 2022Editorial Decision: Revise Minor
14 May 20221st Revision Received
17 May 2022Submission Checks Completed
17 May 2022Assigned to Editor
17 May 2022Review(s) Completed, Editorial Evaluation Pending
18 May 2022Editorial Decision: Accept
